Skip to main content

Midamor Side Effects

Generic name: amiloride

Medically reviewed by Drugs.com. Last updated on May 27, 2023.

Note: This document contains side effect information about amiloride. Some dosage forms listed on this page may not apply to the brand name Midamor.

Applies to amiloride: oral tablet.

Warning

Oral route (Tablet)

Amiloride may cause hyperkalemia, which if uncorrected, is potentially fatal. Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. This incidence is greater in patients with renal impairment, diabetes mellitus (with or without recognized renal insufficiency), and in the elderly. Monitor serum potassium levels carefully in any patient receiving amiloride.

Serious side effects of Midamor

Along with its needed effects, amiloride (the active ingredient contained in Midamor) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking amiloride:

More common

Less common

Rare

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking amiloride:

Symptoms of overdose

Other side effects of Midamor

Some side effects of amiloride may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Rare

For Healthcare Professionals

Applies to amiloride: compounding powder, oral tablet.

Metabolic

Metabolic side effects are the most common. Amiloride (the active ingredient contained in Midamor) may cause hyperkalemia in up to 10% of patients, although the risk is decreased to about 1% to 2% when thiazide or loop diuretics are coadministered. Patients with diabetes or who are on other potassium-sparing therapy, ACE inhibitors, or potassium supplementation are predisposed to amiloride-induced hyperkalemia.[Ref]

Cases of severe hyponatremia have been reported during hydrochlorothiazide-amiloride therapy. In 3 cases, the patients subsequently did well with hydrochlorothiazide and potassium supplementation, suggesting a significant role for amiloride in the development of their hyponatremia.

Significantly elevated serum uric acid, cholesterol, and triglyceride levels have been associated with combination hydrochlorothiazide-amiloride therapy. These metabolic abnormalities may not be due to amiloride since they are reported during hydrochlorothiazide monotherapy.

Amiloride is known to cause significant elevations in serum aldosterone, renin, and angiotensin II levels.[Ref]

Renal

Renal side effects including renal insufficiency is unusual after amiloride (the active ingredient contained in Midamor) monotherapy because it is only a weak diuretic.[Ref]

Gastrointestinal

Gastrointestinal complaints of diarrhea, nausea, constipation, anorexia, and general abdominal pain occur less than 5% of patients.[Ref]

Nervous system

Nervous system side effects occur in less than 3% of patients, and include headache, weakness, and fatigue. Encephalopathy may be induced by amiloride-associated metabolic changes in some patients with severe liver disease.[Ref]

Cardiovascular

Cardiovascular side effects are mainly limited to the increased risk of hyperkalemia-induced arrhythmias in patients at risk for arrhythmias. Angina pectoris, arrhythmias, and orthostatic hypotension are reported in less than 1% of patients.[Ref]

Genitourinary

Genitourinary problems include rare complaints of impotence. Polyuria and urinary frequency are reported in less than 1% of patients.[Ref]

References

1. Vidt DG. Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic. Pharmacotherapy. 1981;1:179-86.

2. Tarssanen L, Huikko M, Rossi M. Amiloride-induced hyponatremia. Acta Med Scand. 1980;208:491-4.

3. Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J. Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients. Clin Pharmacol Ther. 1983;34:448-53.

4. McNay JL, Oran E. Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870). Metabolism. 1970;19:58-70.

5. Davidson C, Burkinshaw L, Morgan DB. The effects of potassium supplements, spironolactone or amiloride on the potassium status of patients with heart failure. Postgrad Med J. 1978;54:405-9.

6. Maddox RW, Arnold WS, Dewell WM. Extreme hyperkalemia associated with amiloride . South Med J. 1985;78:365.

7. Millar JA, Fraser R, Mason P, Leckie B, Cumming AM, Robertson JI. Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects. Br J Clin Pharmacol. 1984;18:369-75.

8. Schiffl H, Schollmeyer P. Clinical efficacy and safety of long-term diuretic treatment in renal parenchymal hypertension. Int J Clin Pharmacol Ther Toxicol. 1985;23:585-8.

9. Product Information. Midamor (amiloride). Merck & Co., Inc. 2001;PROD.

10. Lynn KL, Bailey RR, Swainson CP, Sainsbury R, Low WI. Renal failure with potassium-sparing diuretics. N Z Med J. 1985;98:629-33.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.